Compare · AZN vs ONC
AZN vs ONC
Side-by-side comparison of AstraZeneca PLC (AZN) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 6.1x ONC ($42.53B).
- AZN has been more active in the news (18 items in the past 4 weeks vs 3 for ONC).
- AZN has more recent analyst coverage (25 ratings vs 7 for ONC).
- Company
- AstraZeneca PLC
- BeOne Medicines Ltd.
- Price
- -
- -
- Market cap
- $258.47B
- $42.53B
- 1M return
- -
- +4.46%
- 1Y return
- -
- +17.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2016
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 7
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest ONC
- SEC Form 4 filed by BeOne Medicines Ltd.
- SVP, General Counsel Lee Chan Henry sold $418,125 worth of American Depositary Shares (1,115 units at $375.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Chair, Scientific Advisory Brd Wang Xiaodong exercised 31,028 units of American Depositary Shares at a strike of $36.90 and sold $11,318,558 worth of American Depositary Shares (31,028 units at $364.79) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.
- Chair, Scientific Advisory Brd Wang Xiaodong sold $13,366,092 worth of American Depositary Shares (38,287 units at $349.10) as part of a pre-agreed trading plan and exercised 31,027 units of American Depositary Shares at a strike of $36.90, closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Ball Titus B. sold $46,974 worth of American Depositary Shares (132 units at $355.86), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
- BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
- BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
- President and COO Wu Xiaobin sold $106,400 worth of American Depositary Shares (280 units at $380.00) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)